About Transmembrane domain-containing protein TMIGD3
Transmembrane domain-containing protein TMIGD3 (TMIGD3) is a protein
from Homo sapiens identified by UniProt accession
P0DMS9, 266 residues long.
MolForge cross-references it against 0 known binders and
65 disease associations.
Target properties
| Protein name | Transmembrane domain-containing protein TMIGD3 |
|---|
| UniProt accession | P0DMS9 |
|---|
| Gene | TMIGD3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 266 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (65)
Diseases linked to this target (Open Targets).
- self reported educational attainment · score 0.10
- leukocyte count · score 0.08
- mathematical ability · score 0.08
- osteosarcoma · score 0.07
- neutrophil count · score 0.07
- joint disease · score 0.07
- neoplasm · score 0.06
- myeloid white cell count · score 0.06
- high altitude adaptation · score 0.05
- essential thrombocythemia · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P0DMS9-F1 | alphafold | PREDICTED | 70.49 | — |
Amino-acid sequence (266 residues)
MEGSPAGPIE QKEARWESSW EEQPDWTLGC LSPESQFRIP GLPGCILSFQ LKVCFLPVMW LFILLSLALI SDAMVMDEKV KRSFVLDTAS AICNYNAHYK NHPKYWCRGY FRDYCNIIAF SPNSTNHVAL RDTGNQLIVT MSCLTKEDTG WYWCGIQRDF ARDDMDFTEL IVTDDKGTLA NDFWSGKDLS GNKTRSCKAP KVVRKADRSR TSILIICILI TGLGIISVIS HLTKRRRSQR NRRVGNTLKP FSRVLTPKEM APTEQM
Explore Transmembrane domain-containing protein TMIGD3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets